Gavin MacBeath, PhD
Affiliations: | Chemistry and Chemical Biology | Harvard University, Cambridge, MA, United States |
Area:
Protein SystemsWebsite:
http://macbeath.hms.harvard.edu/Google:
"Gavin MacBeath"Mean distance: 7.11 | S | N | B | C | P |
Parents
Sign in to add mentorDonald M. Hilvert | grad student | 1997 | Scripps Institute | |
(Evolutionary Approaches to the Design of Protein Receptors and Catalysts) | ||||
Stuart L. Schreiber | post-doc | 2001 | Harvard |
Children
Sign in to add traineeJiunn-Ren Chen | grad student | 2008 | Harvard |
Andrew G. Gordus | grad student | 2008 | Harvard |
Michael A. Stiffler | grad student | 2008 | Harvard |
Tanya L. Knickerbocker | grad student | 2009 | Harvard |
Jordan A. Krall | grad student | 2009 | Harvard |
Elsa M. Beyer | grad student | 2010 | Harvard |
Ethan S. Karp | grad student | 2010 | Harvard |
Alexis L. Kaushansky | grad student | 2010 | Harvard |
Grigoriy Koytiger | grad student | 2013 | Harvard |
Albert S. Ye | grad student | 2013 | Harvard |
Richard Baker Jones | post-doc | 2002-2006 | Harvard |
Taran Gujral | post-doc | 2008-2016 | Harvard (Cell Biology Tree) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Casaletto JB, Geddie ML, Abu-Yousif AO, et al. (2019) MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM. Proceedings of the National Academy of Sciences of the United States of America |
Hass H, Masson K, Wohlgemuth S, et al. (2018) Abstract 1312: Predicting ligand-dependent tumors from multi-dimensional signaling features Cancer Research. 78: 1312-1312 |
Mathews S, Finn G, Kudla AJ, et al. (2017) Abstract A19: Identification of Heregulin (HRG) expression as a driver of a difficult-to-treat cancer phenotype and development of a companion diagnostic for the HRG-ErbB3 targeting drug seribantumab Clinical Cancer Research. 23 |
Finn G, Zhang H, Blois A, et al. (2017) Abstract A14: A randomized trial of exemestane +/- seribantumab (MM-121) in postmenopausal women with locally advanced or metastatic ER/PR+ HER2- breast cancer: Final analysis and extended subgroup analysis Clinical Cancer Research. 23 |
Curley MD, Sabnis GJ, Wille L, et al. (2015) Seribantumab, an anti-ERBB3 antibody, delays the onset of resistance and restores sensitivity to letrozole in an estrogen receptor-positive breast cancer model. Molecular Cancer Therapeutics |
Yarar D, Lahdenranta J, Kubasek W, et al. (2015) Heregulin-ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells. Molecular Cancer Therapeutics |
Masson K, Grantcharova V, Burenkova O, et al. (2015) Abstract LB-243: The ErbB3-targeting antibody MM-121 (seribantumab) reverses heregulin-driven resistance to multiple chemotherapies on tumor cell growth Cancer Research. 75 |
Abu-Yousif AO, Casaletto JB, Masson K, et al. (2015) Abstract 1690: Mechanistic characterization of MM-131, a bispecific antibody that blocks c-Met signaling through concurrent targeting of EpCAM Cancer Research. 75: 1690-1690 |
Wainszelbaum MJ, Fessler J, Lahdenranta J, et al. (2015) Abstract LB-C25: Inhibition of ERBB3 with MM-121, IGF1-R with MM-141 or Met with MM-131 increases the activity of EGFR inhibitor MM-151 in colorectal cancer models expressing multiple resistance ligands Molecular Cancer Therapeutics. 14 |
Gujral TS, Chan M, Peshkin L, et al. (2014) A noncanonical Frizzled2 pathway regulates epithelial-mesenchymal transition and metastasis. Cell. 159: 844-56 |